PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

10.1158/1535-7163.MCT-14-0983

10.1200/JCO.2009.26.7609

10.1016/S0140-6736(16)00561-4

10.1056/NEJMoa1606774

10.1158/1078-0432.CCR-13-3271

10.1001/jamaoncol.2018.0013

10.1056/NEJMoa1501824

10.1016/S0140-6736(17)31046-2

10.1056/NEJMoa1510665

10.1016/S0140-6736(16)32455-2

10.1038/nrc.2017.74

10.1016/j.it.2018.04.005

10.1056/NEJMc1713444

10.1126/science.aaa1348

10.1016/j.ccell.2018.03.018

10.1016/j.ccell.2018.04.001

10.1056/NEJMoa1406498

10.1126/science.aad0095

10.1056/NEJMoa1500596

Spranger, 2013, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells, Sci Transl Med, 5, 10.1126/scitranslmed.3006504

10.1016/j.celrep.2017.04.031

10.1056/NEJMoa1801946

10.1038/nature12477

Mandal, 2016, The head and neck cancer immune landscape and its immunotherapeutic implications, JCI Insight, 1, 10.1172/jci.insight.89829

10.1158/2326-6066.CIR-13-0034

Derks, 2016, Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers, Oncotarget, 7, 32925, 10.18632/oncotarget.9076

10.5858/arpa.2013-0610-CP

10.1186/s13073-017-0424-2

10.1038/nbt.2696